Employers aren't overhauling drug plan design for GLP-1 generics just yet as savings still remain out of reach, say insurers
Lilly and Novo cut prices as the obesity drug market races toward US$100 billion by 2030
Strict criteria, no price tag, and a 2027 filing leave plan sponsors watching from the sidelines
Novo Nordisk Canada's Adam Marsella explains how a new savings program aims to support employees on Ozempic amid generic rollout
The drugmaker says it needs more time to finish manufacturing and quality-control data for regulators
Researchers put the added odds at 37 to 68%, though absolute risk stays low
